PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · May 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a rare and aggressive type of cancer called neuroendocrine carcinoma (NEC) and mixed adeno-neuroendocrine carcinoma (MANEC). These cancers are challenging to treat due to their rarity and the fact that they often cannot be removed through surgery. The goal of the trial is to better understand the characteristics of these cancers, which can help doctors find the best ways to treat patients with these conditions.

To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of unresectable locally advanced or metastatic NEC or MANEC, as verified by a specialized doctor. Participants should also have some available tumor tissue for testing, or be willing to have a new biopsy if needed. Throughout the study, participants can expect to undergo various assessments and tests to gather important information about their cancer. This trial is currently recruiting patients, and it aims to improve understanding and treatment options for those facing these difficult-to-treat cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological diagnosis of unresectable locally advanced or metastatic NEC or MANEC confirmed by an expert-pathologist
• • EP-primary site (included unknown primary site
• • Age \> 18 years
• • Signed written informed consent
• • Performance status ≤2
• • Available tumor tissue (formalin-fixed paraffin-embedded, FFPE) (preferably within 6 months). If the tumor contained in FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut. Preferably, 25 slides should be provided (minimum of 15 slides). If tumor tissue is not available, patients should be willing to undergone to a new biopsy.
• Exclusion Criteria:
• • Diagnosis of well-differentiated NEN (G1, G2, G3)
• • Collision tumors
• • Cytological diagnosis of NEC or MANEC or not availability of tumor tissue for pathological analysis.
• • Concurrent neoplastic disease (e.g. Advanced breast or prostatic cancer in hormonal treatment, hematologic diseases)